Up-regulation of neural and cell cycle-related microRNAs in brain of amyotrophic lateral sclerosis mice at late disease stage by Stefania Marcuzzo et al.
Marcuzzo et al. Molecular Brain  (2015) 8:5 
DOI 10.1186/s13041-015-0095-0RESEARCH Open AccessUp-regulation of neural and cell cycle-related
microRNAs in brain of amyotrophic lateral
sclerosis mice at late disease stage
Stefania Marcuzzo†, Silvia Bonanno†, Dimos Kapetis, Claudia Barzago, Paola Cavalcante, Sara D’Alessandro,
Renato Mantegazza* and Pia BernasconiAbstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by selective motor
neuron degeneration in motor cortex, brainstem and spinal cord. microRNAs (miRNAs) are small non-coding RNAs that
bind complementary target sequences and modulate gene expression; they are key molecules for establishing a
neuronal phenotype, and in neurodegeneration. Here we investigated neural miR-9, miR-124a, miR-125b, miR-219,
miR-134, and cell cycle-related miR-19a and -19b, in G93A-SOD1 mouse brain in pre-symptomatic and late stage disease.
Results: Expression of miR-9, miR-124a, miR-19a and -19b was significantly increased in G93A-SOD1 whole brain at late
stage disease compared to B6.SJL and Wt-SOD1 control brains. These miRNAs were then analyzed in manually dissected
SVZ, hippocampus, primary motor cortex and brainstem motor nuclei in 18-week-old ALS mice compared to same age
controls. In SVZ and hippocampus miR-124a was up-regulated, miR-219 was down-regulated, and numbers of neural
stem progenitor cells (NSPCs) were significantly increased. In G93A-SOD1 brainstem motor nuclei and primary motor
cortex, miR-9 and miR-124a were significantly up-regulated, miR-125b expression was also increased. miR-19a and -19b
were up-regulated in primary motor cortex and hippocampus, respectively. Expression analysis of predicted miRNA
targets identified miRNA/target gene pairs differentially expressed in G93A-SOD1 brain regions compared to controls.
Conclusions: Hierarchical clustering analysis, identifying two clusters of miRNA/target genes, one characterizing
brainstem motor nuclei and primary motor cortex, the other hippocampus and SVZ, suggests that altered expression of
neural and cell cycle-related miRNAs in these brain regions might contribute to ALS pathogenesis in G93A-SOD1 mice.
Re-establishing their expression to normal levels could be a new therapeutic approach to ALS.
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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegen-
erative disease characterized by selective motor neuron
degeneration, which leads to atrophy of the associated
muscles [1]. Ten percent of ALS patients have genetically
determined disease caused by mutations in a heteroge-
neous set of genes [1]. Despite increasing knowledge of
pathogenetic mechanisms, no effective treatments are
available for ALS, highlighting the need to identify add-
itional mechanisms that can serve as therapeutic targets.* Correspondence: renato.mantegazza@istituto-besta.it
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unless otherwise stated.The G93A-SOD1 transgenic mouse model of ALS, which
overexpresses the G93A mutated human SOD1 gene,
shows symptoms and neuropathological features similar to
those of human ALS [2]. By magnetic resonance imaging
(MRI) we detected skeletal muscle atrophy in G93A-SOD1
mice at a very early stage, in the absence of motor symp-
toms or neurodegenerative changes in brainstem motor
nuclei, suggesting that neural deficits develop well before
the disease becomes clinically evident [3].
Proliferation and differentiation of neural stem proge-
nitor cells (NSPCs) have been found altered in various
neurodegenerative conditions [4,5]. In ALS mice, as the
disease progresses, NSPCs attempt to proliferate in the
subventricular zone (SVZ) [6] and subgranular zone (SGZ)ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vous system [8,9] – and also in motor cortex [6]. A signifi-
cant increase in NSPC number has also been reported in
brainstem motor nuclei of G93A-SOD1 mice [10], in asso-
ciation with selective neuronal degeneration as revealed by
MRI [11]. Proliferating NSPCs and neuroblasts have also
been identified in the SVZ of an ALS patient with fronto-
temporal dementia, suggesting that neural proliferation
takes place in response to the disease [12].
MicroRNAs (miRNAs) are small non-coding RNAs that
bind complementary target sequences to modulate gene
expression; they are key molecules controlling cell prolifer-
ation, differentiation and neurogenesis [13-19]. In particu-
lar they are known to be involved both in establishing the
neuronal phenotype and in neurodegeneration [20-26]. In
fact miRNAs have been found either up-regulated or
down-regulated in ALS spinal cord, muscle tissue and per-
ipheral blood mononuclear cells (reviewed in ref. [27]).
We recently found that the expression of neural (miR-9,
miR-124a) and cell cycle-related (miR-19a and -19b) miR-
NAs was significantly associated with altered neuronal
fate of cultured ependymal stem/progenitor cells iso-
lated from spinal cord of ALS mice, and that these al-
terations became more marked as disease progressed
[28], suggesting that these miRNAs are involved in ALS
pathogenesis and progression.
Taking these spinal cord findings as our starting point,
in the present study we investigated whether disease
progression in G93A-SOD1 mice was associated with
altered expression of miRNAs in various brain regions.
We investigated miR-9, miR-124a, miR-19a and -19b, as
in our previous study [28]. We also investigated miR-125
and miR-219, implicated in astrocyte and oligodendro-
cyte regulation [29,30], since the ALS brain is known to
be characterized by neurodegeneration and astrogliosis.
Finally, we investigated miR-134, implicated in neuronal
morphogenesis and synaptic plasticity [31].
In the present study, we first investigated the expression
of miR-9, miR-124a, miR-19a, miR-19b and miR-134 in
the whole brain of G93A-SOD1 mice in comparison with
that of B6.SJL and Wt-SOD1 control mice, in asymptom-
atic (week 8) and late stage disease (week 18). We found
that the expression of miR-134 did not differ significantly
between ALS and control brain, while the expression of
the other miRNAs did. We next analyzed the expression
of miR-9, miR-124a, miR-19a and -19b, miR-125 and miR-
219 in manually dissected SVZ, hippocampus, primary
motor cortex and brainstem motor nuclei in 18-week-old
ALS mice compared to same age controls. We found that
the expression of all the miRNAs investigated was signifi-
cantly altered in several of these brain areas.
Our findings show that the expression of miRNAs regu-
lating neural and cell cycle processes is altered in G93A-
SOD1 mouse brain in late stage disease. We propose thatnormalization of altered miRNA expression might be a
useful therapeutic approach to ALS.
Results
miRNA expression in G93A-SOD1 whole brain in relation
to disease progression
At 8 weeks expression levels of miR-9, miR-124a, miR-19a
and -19b did not differ significantly between whole brains of
G93A-SOD1, B6.SJL and Wt-SOD1 mice, except for miR-
19a, which was significantly down-regulated in ALS brain
(p < 0.05) (Figure 1). At week 18, miR-9, miR-124a, miR-19a
and -19b levels were significantly higher in G93A-SOD1
than control brains (p < 0.01 both B6.SJL and Wt-SOD1)
(Figure 1). In addition, miR-9 was significantly up-regulated
in G93A-SOD1 brain compared to week 8 (p < 0.01).
As is evident in Figure 1, expression levels of the se-
lected miRNAs did not differ between Wt-SOD1 and B6.
SJL controls, indicating that expression of the human
wild-type SOD1 transgene does not affect the miRNA
expression in these mice, and that Wt-SOD1 mice are
suitable controls for this study.
Interestingly, at week 18, expression levels of miR-9 and
miR-124a, but not miR-134, were significant lower in
G93A-SOD1 whole spinal cord than in Wt-SOD1 spinal
cord (p < 0.05 and p < 0.01, respectively), whereas miR-19a
and -19b expression levels were significantly higher in ALS
than Wt-SOD1 mice (p < 0.01 and p < 0.05, respectively)
(Additional file 1: Figure S1).
miRNA expression in selected brain regions
We next wondered whether altered miRNA expression in
the brain of 18-week-old ALS mice would be evident in
specific brain regions concerned with neurogenesis (SVZ
and hippocampus) and affected by ALS (primary motor
cortex and brainstem motor nuclei). We also analyzed
miR-125b, marker of reactive astrocytes [29], and miR-219,
marker of oligodendrocyte differentiation [30], to inves-
tigate glial cell involvement in these brain regions. We
found that miR-124a expression was significantly greater in
SVZ, hippocampus, primary motor cortex, and brainstem
motor nuclei of ALS than Wt-SOD1 mice (p < 0.01). miR-9
expression was lower in SVZ and hippocampus, and
significantly greater in primary motor cortex and brainstem
motor nuclei (p < 0.01) in ALS compared to control
(Figure 2A). miR-19a was significantly down-regulated in
hippocampus and brainstem motor nuclei and significantly
up-regulated in primary motor cortex of G93A-SOD1 com-
pared to control (p < 0.01). miR-19b was up-regulated in
hippocampus (p < 0.05) and down-regulated in primary
motor cortex and brainstem motor nuclei (p < 0.05 and p <
0.01, respectively) (Figure 2B). miR-125b was significantly
down-regulated in G93A-SOD1 SVZ and hippocampus
(p < 0.01) and significantly up-regulated in primary motor
cortex (p < 0.01). Finally, miR-219 was significantly lower in
Figure 1 Neural and cell cycle-related miRNAs are altered in G93A-SOD1 mouse brain as disease progresses. RT-PCR analysis of brain-specific (A)
and cell cycle-related (B) miRNAs in total RNA extracted from whole brain of G93A-SOD1, B6.SJL and Wt-SOD1 mice, at postnatal weeks 8 and 18 (ten mice
per group). Each point represents a single brain. Relative expression data are presented as means ± SD. *p< 0.05; **p< 0.01; limma moderated t-test.
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125b and miR-219 tended to be expressed at higher levels
(not significant) in cervical, thoracic and lumbar spinal cord
of ALS than control mice (Additional file 2: Figure S2).
Expression of miRNA targets
Based on miRWalk database prediction [32] and on the lit-
erature [28,30,33-37], the following miRNA target mRNAsFigure 2 Brain-specific, cell cycle- and glia-related miRNA expression
brain. RT-PCR analysis of brain-specific (A), cell cycle- (B) and glia- (C) relat
motor cortex (MC), and brainstem motor nuclei (MN) of G93A-SOD1 and W
expression ± SD of 5 mice per group. *p < 0.05; **p < 0.01; limma moderatewere identified: cyclin D2 (Ccnd2), Dlx2, forkhead box pro-
tein J3 (FoxJ3), hairy and enhancer of split 1 (Hes1), Jagged
1 (Jag1), MAP kinase interacting serine/threonine kinase 2
(Mknk2), nuclear receptor subfamily 2 (Nr2e1), phos-
phatase and tensin homolog (Pten), specific E3 ubi-
quitin protein ligase 1 (Smurf1), suppressor of cytokine
signaling 1 (Socs1), sex determining region Y(SRY)-box
6 (Sox6), Sox9 and signal transducer and activator ofis altered compared to control in different regions of G93A-SOD1
ed miRNAs in subventricular zone (SVZ), hippocampus (H), primary
t-SOD1 brain at late stage disease. Data are means of relative
d t-test.
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quantified in 18-week-old ALS and control brain. Jag1,
Nr2e1, and Smurf1 mRNA levels did not differ signifi-
cantly between ALS and controls in any brain area
(data not shown). In SVZ, all other mRNAs, except
Socs1, were significantly more expressed in ALS than
control brain (p < 0.05 and p < 0.01, Figure 3). InFigure 3 Altered expression of predicted miRNA targets in distinct re
SD of log2 of fold changes of 2-ΔCT expression in G93A-SOD1 relative to W
in mRNA (*p < 0.05, **p < 0.01, grey bars) and miRNA (*p < 0.05, **p < 0.01,
moderated t-test.hippocampus, primary motor cortex and brainstem
motor nuclei, the mRNAs of most putative target genes
were non-significantly reduced in ALS compared to
control; exceptions were a significant increase of Dlx2
in hippocampus, and a significant decrease of Socs1 in
primary motor cortex and brainstem motor nuclei (p <
0.05, Figure 3).gions of G93A-SOD1 mouse brain. Data are presented as means ±
t-SOD1 (grey bars) at late stage disease (week 18). Significant changes
light grey bars) expression relative to control are indicated. Limma
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18-week-old ALS mouse brain
Pearson’s correlation analysis was applied to each miRNA
and its putative target, to provide evidence of relationships
between them, in brain regions of 18-week-old ALS mice.
Since miRNAs mainly act as negative regulators, we
focused on inverse correlations, considering coefficients
(r) less than −0.5 as indicating a good inverse correlation.
The results of the analysis are reported in Table 1. The
most conspicuous correlations were found in areas (pri-
mary motor cortex and brainstem motor nuclei) charac-
terized by marked motor neuron loss.
NSPCs in SVZ and hippocampus of ALS mice
The SVZ is the primary source of new neurons in adult
brain. Neurons arise from unipolar bipolar type B stem
cells that express nestin and vimentin and/or glial fibrillary
acidic protein (GFAP): they give rise to transit-amplifying
type C cells, and in turn produce type A neuroblasts
expressing Dlx2 – which are migratory and prolif-
erative neuronal precursors [8]. ImmunohistochemicalTable 1 List of gene targets for each miRNA and inverse corre
G93A-SOD1 mice
miRNA Gene target
miR-124a - Distal-less homeobox 2 (Dlx2)
- Jagged (Jag1)
- Sex determining region Y(SRY)-box 9 (Sox9)
- Signal transducer and activator of transcription 3 (STAT3)
miR-9 - Hairy and enhancer of split (Hes1)
- Nuclear receptor subfamily (Nr2e1)
- Phoshatase and tensin homolog (Pten)
- STAT3
miR-19a - Cyclin D2 (Ccnd2)
- Pten
- Suppressor of cytokine signalling 1 (Socs1)





miR-125b - Forkhead box protein J3 (FoxJ3)
- Sox6
miR-219 - FoxJ3
- MAP kinase interacting serine/threonine kinase 2 (Mknk2)
- Pten
- Specific E3 ubiquitin protein ligase 1 (Smurf1)
miRNA targets were predicted from published data and in-silico modeling using miRW
apps/zmf/mirwalk/). Pearson’s correlation coefficients (r) were used to corroborate relat
mouse brain regions at week 18. Coefficients less than −0.5 (bold) were considered toanalysis for nestin, GFAP and vimentin revealed signifi-
cantly more unipolar and bipolar cells positive for these
markers in the dorsal and ventral SVZ of 18-week-old
ALS mice compared with same areas in Wt-SOD1 mice
(p < 0.001; Figure 4A-C). We also found significantly
more Dlx2-positive cells in the ventral SVZ of ALS than
Wt-SOD1 mice (p < 0.001; Figure 4D, E). These findings
suggest that neurogenesis is occurring in the SVZ of
ALS mice at late stage disease. In the adult mammalian
brain neurogenesis also occurs in the hippocampal den-
tate gyrus [38]. Immunohistochemical analysis of hippo-
campal dentate gyrus revealed significantly more nestin-
and GFAP-positive NSPCs in 18-week-old ALS mice
than same-age controls (p < 0.05; Figure 5).
Heat map of miRNAs and predicted gene targets in
regions of G93A-SOD1 brain
Figure 6 shows expression levels of miRNAs and target
mRNAs relative to mean values in all brain areas investi-
gated. Hierarchical clustering analysis identified two
clusters of miRNAs and their predicted targets: onelations in each brain region investigated of 18-week old




r > − 0.5 r > − 0.5 r = − 0.96 r = − 0.96
r > − 0.5 r > − 0.5 r > − 0.5 r > − 0.5
r > − 0.5 r > − 0.5 r > − 0.5 r = − 0.51
r > − 0.5 r > − 0.5 r > − 0.5 r = − 0.89
r > − 0.5 r > − 0.5 r > − 0.5 r > − 0.5
r > − 0.5 r > − 0.5 r > − 0.5 r > − 0.5
r > − 0.5 r > − 0.5 r > − 0.5 r = − 0.54
r = − 0.77 r = − 0.95 r > − 0.5 r = − 0.51
r > − 0.5 r = − 0.76 r > − 0.5 r > − 0.5
r > − 0.5 r > − 0.5 r > − 0.5 r > − 0.5
r > − 0.5 r = − 0.88 r > − 0.5 r > − 0.5
r = − 0.96 r > − 0.5 r = − 0.96 r > − 0.5
r > − 0.5 r > − 0.5 r > − 0.5 r > − 0.5
r = − 0.85 r > − 0.5 r > − 0.5 r > − 0.5
r = − 0.90 r > − 0.5 r > − 0.5 r > − 0.5
r = − 0.83 r > − 0.5 r = − 0.96 r > − 0.5
r > − 0.5 r > − 0.5 r > − 0.5 r > − 0.5
r > − 0.5 r > − 0.5 r = − 0.96 r > − 0.5
r > − 0.5 r > − 0.5 r = − 0.96 r > − 0.5
r > − 0.5 r > − 0.5 r = − 0.99 r > − 0.5
r > − 0.5 r > − 0.5 r = − 0.50 r > − 0.5
r > − 0.5 r > − 0.5 r > − 0.5 r > − 0.5
alk database and default score parameters (http://www.umm.uni-heidelberg.de/
ionships between miRNAs and target mRNA expression levels in G93A-SOD1
indicate a good inverse correlation.
Figure 4 Increased numbers of differentiating NSPCs in SVZ of G93A-SOD1 brain. (A) Confocal microscopy images of dorsal and ventral
regions of SVZ in G93A-SOD1 and Wt-SOD1 brain at postnatal week 18, stained for nestin (green), GFAP (red), and vimentin (blue). Scale bar = 50 μm.
(B) Quantification of nestin-, GFAP-, and vimentin-positive cells in SVZ of G93A-SOD1 and Wt-SOD1 mice. Data are means ± SD of 3 mice per group.
**p < 0.001; limma moderated t-test. (C) Hematoxylin and eosin staining of SVZ sections adjacent to those analyzed by confocal microscopy. Scale
bar = 50 μm. D: dorsal. V: ventral. (D) Confocal microscopy images showing Dlx2-stained cells in ventral SVZ in G93A-SOD1 and Wt-SOD1 brain. Scale
bar = 50 μm. (E) Quantification of Dlx2-positive cells in G93A-SOD1 and Wt-SOD1 SVZ. Data are means ± SD of 3 mice per group. **p < 0.001; limma
moderated t-test.
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motor cortex; the other characterizing hippocampus and
SVZ.
Discussion
In the present study we have found that in whole brain
and brain regions concerned with neurogenesis (SVZ and
hippocampus) and affected by motor neuron degeneration(primary motor cortex and brainstem motor nuclei),
altered expression of neural fate miR-124a and miR-9
(but not miR-134), cell cycle-related miR-19a and -19b,
astrocyte-related miR-125b and oligodendrocyte -related
miR-219 occur in late stage disease (18 weeks).
miR-124a, highly conserved during evolution, is one of
the most highly expressed miRNAs in the CNS [15,39].
In mouse it plays a key role in promoting neuronal
Figure 5 Increased numbers of NSPCs in hippocampus of G93A-SOD1 mouse at postnatal week 18. (A) Confocal microscopy images of
hippocampus dentate gyrus (DG) in G93A-SOD1 and Wt-SOD1 mouse, stained for nestin (green) and GFAP (red). Scale bar = 50 μm. Hematoxylin
and eosin staining of hippocampus (lower panel) sections adjacent to those analyzed by confocal microscopy. Scale bar = 50 μm. (B) Quantification of
nestin- and GFAP-positive cells in G93A-SOD1 and Wt-SOD1 brain. Data are means ± SD of 3 mice per group. *p < 0.05; limma moderated t-test.
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non-neuronal genes such as Sox9 [15]. We found miR-
124a up-regulation in SVZ, hippocampus, primary motor
cortex and brainstem motor nuclei of 18-week-old G93A
mice probably reflecting active neuronal differentiation in
response to motor neuron degeneration [5,6,40]. NSPCs
are normally quiescent in the brain, but under patho-
logical conditions switch to active in neurogenic regions
[41]. NSPCs can generate Dlx2-expressing neuroblasts in
SVZ [8,15]. It is noteworthy that we found significantly
more Dlx2-positive neuroblasts in ALS SVZ than control.
We also found a good inverse correlation between miR-
124a and Sox9 expression in brainstem motor nuclei – a
region markedly affected by motor neuron loss in ALS, as
also found in our MRI study on late stage disease ALS
mice [3].
miR-9 – an evolutionarily-conserved brain-enriched
miRNA [39] – might play an important role in ALS neu-
rodegeneration. We found significantly increased expres-
sion of miR-9 in primary motor cortex and brainstem
motor nuclei, and significantly down-regulated miR-9 in
SVZ and hippocampus. Our finding that miR-124a and
miR-9 are up-regulated in primary motor cortex and
brainstem motor nuclei therefore suggests a compensatoryresponse to motor neuron degeneration in these areas
highly affected by the disease process.
Both miR-124a and miR-9 target STAT3 [42]. In devel-
oping CNS, STAT3 activation reduces neurogenesis from
neural stem cells [43] in favor of differentiation to astro-
cytes [44]. We found a good negative correlation between
miR-124a and miR-9 and STAT3 in brainstem motor
nuclei, again suggesting that neural precursors are being
directed toward a neuronal rather than glial fate in this
damaged area. However in brainstem STAT3 reduction
was not significant. miR-9 also correlated negatively with
STAT3 in SVZ and hippocampus: STAT3 levels were
slightly increased in these regions while miR-9 was signifi-
cantly down-regulated, again suggesting compromised
neurogenesis in these neurogenic areas.
The later finding is interesting, since miR-9’s absence
in mice causes the premature birth of cortical neurons
and suppression of neural precursor proliferation in the
ventricular and subventricular zones [45] and this might
compromise neuroregeneration in the ALS mouse.
In our previous study on cultured ependymal stem/
progenitor cells isolated from G93A-SOD1 mouse spinal
cord at week 18, miR-9 correlated negatively with STAT3 in
neural differentiated cells [28], again suggesting involvement
Figure 6 Heat map of miRNAs and predicted gene targets in regions of G93A-SOD1 mouse brain. Regions investigated were brainstem
motor nuclei, primary motor cortex, hippocampus and SVZ at week 18. Expression data are means of log2 fold changes (relative to mean values
for all brain areas investigated). Blue indicates down-regulation and red indicates up-regulation of miRNAs and predicted gene targets, respectively.
Hierarchical clustering analysis identifies two clusters of miRNAs and their predicted targets: one characterizing brainstem motor nuclei and primary
motor cortex (areas of neurodegeneration); the other characterizing hippocampus and SVZ (areas of neurogenesis).
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signaling pathways.
With regard to miR-19a and -19b, these are involved
in cell cycle regulation and their expression is enhanced
in several stem cell types [13,46]. We found that miR-
19a was significantly down regulated in hippocampus,
while, as expected, Ccnd2 levels correlated inversely with
miR-19a. Ccnd2 is known to enhance proliferation [47].
We there conjecture Ccnd2 activity is tending to en-
hance proliferation in this brain area, as also suggested
by our finding of increased number of NSPCs in this
brain region.
We found that miR-19b was down-regulated in motor
cortex and the levels of predicted target Sox6 correlated
negatively with miR-19b in this brain area. Sox6 is
known to promote the survival and renewal of neuralprecursor cells and is enhancing the survival of neural
precursors in this brain area [48].
As regards miR-125b, which is expressed in neurons
and astrocytes and seems to be involved in the astrogliosis
that occurs in Alzheimer disease [49], we found that this
miRNA was significantly down-regulated in SVZ and
hippocampus – areas in which differentiating NSPCs were
significantly increased in G93A-SOD1 mice compared
to control – but significantly up-regulated in primary
motor cortex in association with reduced levels of Sox6.
These data suggest that miR-125b overexpression in pri-
mary motor cortex and also spinal cord (Additional file 2:
Figure S2) is functionally associated with the corticospinal
tract degeneration characteristic of ALS.
Our finding of significantly decreased miR-219 expression
in SVZ suggests an imbalance between oligodendrocyte
Marcuzzo et al. Molecular Brain  (2015) 8:5 Page 9 of 13and neuronal precursors during NSPC differentiation in
that brain region, as further supported by the increased
numbers of Dlx2-positive neuroblasts found there.
When we applied hierarchical clustering to the expression
of miRNAs and their putative mRNA targets, two clusters
emerged: one characterizing brainstem motor nuclei and
primary motor cortex; the other characterizing hippocam-
pus and SVZ (Figure 6). This finding is noteworthy since
primary motor cortex and brainstem motor nuclei are the
regions rich in upper and lower motor neuron cell bodies,
whereas SVZ and hippocampus are neurogenic areas where
(unsuccessful) neurogenesis in response to motor neuron
degeneration seems to be occurring.
In the present study we focused on expression levels of
mature miRNAs; however studies have shown that various
regulatory factors are involved in miRNA biogenesis
(reviewed in ref. [27]) and that miRNA expression is
tightly regulated by mechanisms that influence transcrip-
tion, processing and turnover (reviewed in ref. [27,50]).
Several gene-products associated with ALS have been also
shown to be involved in miRNA pathways. For example,
TAR DNA-binding protein TDP-43 – component of Dicer
and Drosha complexes and important for miRNA biogen-
esis – selectively regulates pri-miRNA processing by bind-
ing to primary transcripts of specific miRNAs. FUS/
translocated in liposarcoma protein also binds pre-mRNA
molecules. Both TDP-43 and FUS/TLS influence the fate
of miRNAs by regulating splicing, transport, stability, and
translation (reviewed in ref. [27]). These findings suggest
that mutations in ALS-related genes can lead to altered
miRNA biogenesis and function, which may in turn con-
tribute to the ALS phenotype. We hope to present the
results of our ongoing studies on alterations in miRNA
biogenesis pathways in the mouse ALS model in a subse-
quent publication.
Conclusions
The aberrant expression of miRNAs in many human dis-
eases [51] makes them potential drug targets, and artificial
modulation of dysregulated endogenous miRNAs, through
use of antagonists or mimics, is being increasingly consid-
ered for therapy [52-55]. We have identified miRNAs,
which appear to be involved in the pathogenesis of ALS in
mice: these should be further investigated to develop ther-
apies that can restore normal miRNA levels and hopefully
ameliorate the course of the disease.
Methods
Reagents, source companies and working dilutions are
listed in Table 2.
Animals
Transgenic G93A-SOD1 (B6SJL-Tg(SOD1*G93A)1Gur),
wild-type (Wt)-SOD1 (B6SJLTg(SOD1)2Gur/J) and B6.SJL mice were maintained and bred at the animal house of
the C Besta Neurological Institute, in compliance with in-
stitutional guidelines and international law (EEC Council
Directive 86/609, OJL 358, 1, December 12, 1987, NIH
Guide for the Care and Use of Laboratory Animals, U.S.
National Research Council, 1996). G93A- and Wt-SOD1
progeny were identified by RT-PCR of the human SOD1
gene [3]. Males were used in all experiments. They were
killed by exposure to CO2 at week 8 (pre-symptomatic) or
week 18 (late stage disease) [3].
Isolation of specific brain and spinal cord regions
Each brain region was identified with the aid of the coor-
dinates shown in the mouse brain atlas [56]. The region
containing brainstem motor nuclei (including facial, am-
biguous, trigeminal and hypoglossal nuclei) was also rec-
ognized and isolated with the aid of MR images, as
described in a previous paper [3]. We manually dissected
out the brain regions of interest using a dissecting micro-
scope and scalpel, as described by Matsumura et al. [38].
We initially removed the olfactory bulbs with a coronal
cut about 2 mm from the rostral surface of the frontal
lobes. We then cut a 3 mm-thick slice containing the pri-
mary motor cortex, secondary motor cortex and dorsal
and ventral parts of the subventricular zone (SVZ). In this
slice, we identified the corpus callosum as separating the
motor cortex (above) from the SVZ (below). The SVZ
was also identified as forming the wall of the lateral
ventricles. A 2 mm-thick slice was taken next which
contained the hippocampus, readily identified by visual
inspection, which was carefully dissected out. A succes-
sive coronal section of about 2 mm thickness was
taken, which clearly showed the cerebral aqueduct.
Around and underlying this were the brainstem motor
nuclei and the visually evident trigeminal nucleus. This
area was separated out using a scalpel. A final 1 mm-
thick slice was taken. This contained the evident fourth
ventricle; below this continued the area of the brain-
stem motor nuclei, which was also separated out using
a scalpel and united with the material of the previous
section.
Total spinal cord was dissected out and cut into cer-
vical, thoracic, and lumbar sections. The cervical section
comprised the part from the top of the spinal cord to
the cervical enlargement. The thoracic segment was that
from the cervical enlargement to the last rib. The
remaining spinal cord was the lumbar segment.
Quantitative real-time PCR to determine miRNAs
Total RNA was extracted with TRIzol reagent from:
whole brain (300–400 mg); spinal cord (100–200 mg);
SVZ, hippocampus, primary motor cortex and brainstem
motor nuclei and also cervical, thoracic and lumbar
spinal cord. The RNA was retrotranscribed to cDNA
Table 2 Reagents, source companies and working dilutions
Source
Animals G93A-SOD1 (B6SJL-Tg(SOD1*G93A)1Gur) Charles River (Wilmington, MA)
Wild-type (Wt)-SOD1 (B6SJLTg(SOD1)2Gur/J) Charles River (Wilmington, MA)
B6.SJL Charles River ((Wilmington, MA)
Working dilution
Primary -Rabbit anti-mouse glial fibrillary acidic protein
Antibodies (GFAP) IgG antibody Dako Cytomation (Glostrup, Denmark) 1:300
-Chicken anti-mouse vimentin IgG antibody Novus Biological 1:500
-Mouse anti-mouse nestin IgG antibody Millipore (Billerica, MA) 1:200
-Goat anti-mouse Dlx2 IgG antibody Santa Cruz (Heidelberg, Germany) 1:50
Secondary -Cy3-conjugated goat anti-rabbit IgG Jackson ImmunoResearch (Newmarket, UK) 1:600
antibodies -AMCA-conjugated anti-chicken IgG Jackson ImmunoResearch (Newmarket, UK) 1:100
-Cy2-conjugated goat anti-mouse IgG Jackson ImmunoResearch (Newmarket, UK) 1:200
-Cy2-conjugated donkey anti-goat IgG Jackson ImmunoResearch (Newmarket, UK) 1:200
-Isotype-specific non-immune IgG (control) Dako Cytomation (Glostrup, Denmark) 1:200
-Normal goat serum (control) Vector Laboratories (Peterborough, UK)
Reagents for -Optical Cutting Temperature Compound Bio-Optica (Milan, Italy)
sample conservation
Microscopes -Aperio scanner Nikon (GMBH, Germany)
-Aperio Image Scope v12.0.0.5039 Nikon (GMBH, Germany)
-Eclipse TE-2000-E Nikon (Tokyo, Japan)
Reagents -Trizol Life Technologies (Foster City, MA)
qReal-Time PCR -2100Nano Bioanalyzer Agilent Technologies (Waldbronn, Germany)
-TaqMan MicroRNA reverse Transcription Kit Life Technologies (Foster City, MA)
-miRBase ID mmu-miR-9-5p Life Technologies (Foster City, MA)
-miRBase ID mmu-miR-124-3p Life Technologies (Foster City, MA)
-miRBase ID mmu-miR-134-5p Life Technologies (Foster City, MA)
-miRBase ID mmu-miR-125b-5p Life Technologies (Foster City, MA)
-miRBase ID mmu-miR-219a-5p Life Technologies (Foster City, MA)
-miRBase ID mmu-miR-19a-3p Life Technologies (Foster City, MA)
-miRBase ID mmu-miR-19b-3p Life Technologies (Foster City, MA)
-miRBase ID xtr-miR-24a-3p Life Technologies (Foster City, MA)
Reagents for
miRNA -SuperScript Vilo cDNA Synthesis kit Life Technologies (Foster City, MA)
target validation -Universal PCR master mix Life Technologies (Foster City, MA)
-Taqman Array Fast Plate Life Technologies (Foster City, MA)
-Mm-Ccnd2-Assay ID00438070_m1 Life Technologies (Foster City, MA)
-Mm-Dlx2-Assay ID00438427_m1 Life Technologies (Foster City, MA)
-Mm-Foxj3-Assay ID00554610_m1 Life Technologies (Foster City, MA)
-Mm-Hes1-Assay ID01342805_m1 Life Technologies (Foster City, MA)
-Mm-Jag1-Assay ID00496902_m1 Life Technologies (Foster City, MA)
-Mm-Mknk2- Assay ID00458026_m1 Life Technologies (Foster City, MA)
-Mm-Nr2e1-Assay ID00438427_m1 Life Technologies (Foster City, MA)
-Mm-Pten-Assay ID00477208_m1 Life Technologies (Foster City, MA)
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Table 2 Reagents, source companies and working dilutions (Continued)
-Mm-Smurf1-Assay ID00547102_m1 Life Technologies (Foster City, MA)
-Mm-Socs1-Assay ID01219775_g1 Life Technologies (Foster City, MA)
-Mm-Sox6-Assay ID00488393_m1 Life Technologies (Foster City, MA)
-Mm-Sox9-Assay ID00448840_m1 Life Technologies (Foster City, MA)
-Mm-Stat3-Assay ID01219775_m1 Life Technologies (Foster City, MA)
-Mm-GFAP-Assay ID0125033_m1 Life Technologies (Foster City, MA)
-Mm-18 s-Assay ID03928990_g1 Life Technologies (Foster City, MA)
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primers specific for miR-9, miR-19a, miR-19b, miR-124a,
miR-125b, miR-134, miR-219 and miR-24. miR-24, used
as endogenous control [57] was stably expressed in whole
brain and the brain regions studied of G93A-SOD1, B6.
SJL and Wt-SOD1 mice (as shown by standard deviation
of Ct values < 0.5). cDNA aliquots corresponding to 15 ng
total RNA were amplified by quantitative real time PCR in
triplicate, with Universal PCR master mix and specific
pre-designed TaqMan MicroRNA assays. miRNA levels
were normalized to miR-24 and expressed as fold changes
using the formula 2-ΔCt.
Prediction of miRNA gene targets
miRNA targets were predicted in-silico using the miR-
Walk database using the default score parameters [32].
We also identified potentially dysregulated target genes
from the literature and our previous studies [28,30,33-37].
We chose to include those genes strictly implicated in
cell-cycle regulation and cell function signaling neurogen-
esis. The mRNA targets of each miRNA are listed in
Table 1 and the prediction tool applied to identify them is
reported in the footnote of Table 1.
mRNA real-time PCR
Total RNA, previously examined for miRNA expression in
distinct brain regions, was retrotranscribed using Super-
Script Vilo cDNA Synthesis kit. cDNA (20 ng total RNA)
was amplified by qPCR in duplicate, using Universal PCR
master mix and Taqman Array Fast Plate, assembled with
primer and probe sets for the identified 13 miRNA target
genes and one housekeeping gene, 18s [58]. 18s was stably
expressed in distinct brain regions of G93A-SOD1 and
WT-SOD1 mice; standard deviation of Ct values: < 0.5. In
addition, GFAP mRNA expression levels were measured
as marker for astrocytes.
Immunostaining
Brain tissue was embedded in optimal cutting temperature
compound immediately upon removal and stored at −80°C
pending histological analyses. Cryostat 15 μm-thick sec-
tions were cut in correspondence to SVZ and hippocam-
pus regions, stained with hematoxylin-eosin, and imageswere digitally acquired with the Aperio ScanScope system.
Adjacent sections were fixed in 4% paraformaldehyde,
treated with 0.1% Triton X-100 for 10 min, and washed
with PBS. Sections were then incubated with 10% normal
goat serum or bovine serum albumin and with the fol-
lowing primary antibodies, overnight at 4°C: GFAP, marker
for astrocytes; vimentin, for glial precursors; nestin, for
NSPCs; distal-less homeobox 2 (Dlx2), for neuronal
precursors. After washing, samples were incubated for
1 hour at room temperature with secondary antibodies
(Cy3-conjugated goat anti-rabbit IgG, AMCA-conjugated
anti-chicken IgG, Cy2-conjugated goat anti-mouse IgG or
Cy2-conjugated donkey anti-goat IgG). Negative control
sections were incubated with isotype-specific non-immune
IgG or normal goat serum. Confocal fluorescence images
were captured with a laser scanning. Quantitative evalu-
ation of single positive cells in the SVZ and hippocampus
areas was carried out on ten cryostat sections at X40
magnification for each mouse using the Image Pro-Plus
software (version 1.43 u).Statistical analysis
The limma empirical Bayesian implementation of the t-test
[59] was used to compare experimental data derived from
miRNA and mRNA molecular and immunohistochem-
istry analyses between G93A-SOD1 and control mice. A
Bonferroni correction was applied to control for false
discovery rate; p < 0.05 was considered significant. Pearson
correlation coefficients (r) were determined to identify re-
lationships between miRNAs and target mRNA expression
levels [60] in different brain regions of 18 week-old G93A-
SOD1 mice. The R statistical environment (www.r-project.
org) was used for statistical analyses.Additional files
Additional file 1: Figure S1. Expression levels of neural- and cell cycle-
related miRNAs in G93A-SOD1 spinal cord as disease progresses. RT-PCR
analysis of neural-specific and cell cycle-related miRNAs in total RNA
extracted from whole spinal cord of G93A-SOD1 and Wt-SOD1 mice, at
postnatal week 18 (ten mice per group). Each point represents a single
spinal cord. Relative expression data are presented as mean ± SD. *p < 0.05;
**p < 0.01; limma moderated t-test.
Marcuzzo et al. Molecular Brain  (2015) 8:5 Page 12 of 13Additional file 2: Figure S2. Expression levels of glial-related miRNAs in
spinal cord regions. RT-PCR analysis of miR-125b and miR-219, implicated in
astrocyte and oligodendrocyte functional regulation, in cervical, thoracic and
lumbar spinal cord regions. Total RNA was extracted from cervical, thoracic
and lumbar spinal cord of G93A-SOD1 and Wt-SOD1 mice, at postnatal
week 18 (three mice per group). Relative expression data are presented as
mean ± SD; limma moderated t-test.
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